B29
Biognosis – Development of a novel point of care diagnostic for cancer detection
Ryan C. Pink, Sarah M. Morgan
Cranfield University, Bedfordshire, UK
Background
Biognosis is an EU consortium project which aims to develop a unique label free DNA and protein detection system for bench top point of care medical diagnostics. This should allow fast and reliable in-vitro testing, of an easy-to-use and cost-effective nature is required.
Aims
(a) Development of a unique resonator (FBAR) chip based detection system; (b) Identification and validation of novel markers for breast cancer; and (c) clinical evaluation of the sensor device and end user acceptability
Method
Clinical development for the detection of Breast and Prostate cancer markers with ethical approval, samples are collected from Prostate and Breast cancer patients along with healthy volunteers.These are tested on the system for overall evaluation compared to reference assays. This involves sample preparation and dynamics i.e. the affect of blood on the micro-fluidics of the system, binding materials and optimising calibration steps. Followed by reviewing clinical and public end-user acceptability of such a system.
Results
To be concluded in January 2009
Future prospects for Biognosis
(a) Enable earlier cancer detection and diagnosis with decentralised approach; (b) simplicity and low costs of the system opens up new developing world markets; (c) opportunity to multiplex this system due to pixel detection; and (d) surface functionalisation can be adapted for all biological detection, disease and genetically personalised medicine.
Acknowledgments
Siemens, Medifiq, Uppsala University, Medical University of Innsbruck (MUI), University College London (UCL) and VTT.
